BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19734451)

  • 21. Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl).
    Zeng S; Xu Z; Lipkowitz S; Longley JB
    Blood; 2005 Jan; 105(1):226-32. PubMed ID: 15315962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of fcgamma receptor-mediated phagocytosis by transforming mutants of Cbl.
    Sato N; Kim MK; Schreiber AD
    J Immunol; 1999 Dec; 163(11):6123-31. PubMed ID: 10570302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination.
    Taher TE; Tjin EP; Beuling EA; Borst J; Spaargaren M; Pals ST
    J Immunol; 2002 Oct; 169(7):3793-800. PubMed ID: 12244174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
    Ahmed SF; Buetow L; Gabrielsen M; Lilla S; Sibbet GJ; Sumpton D; Zanivan S; Hedley A; Clark W; Huang DT
    Oncogene; 2021 Mar; 40(12):2149-2164. PubMed ID: 33627783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of function Cbl-c mutations in solid tumors.
    Daniels SR; Liyasova M; Kales SC; Nau MM; Ryan PE; Green JE; Lipkowitz S
    PLoS One; 2019; 14(7):e0219143. PubMed ID: 31260484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
    Grundler R; Miething C; Thiede C; Peschel C; Duyster J
    Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
    An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
    Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
    Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
    Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation.
    Hashimoto K; Matsumura I; Tsujimura T; Kim DK; Ogihara H; Ikeda H; Ueda S; Mizuki M; Sugahara H; Shibayama H; Kitamura Y; Kanakura Y
    Blood; 2003 Feb; 101(3):1094-102. PubMed ID: 12393643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A juxtamembrane tyrosine in the colony stimulating factor-1 receptor regulates ligand-induced Src association, receptor kinase function, and down-regulation.
    Rohde CM; Schrum J; Lee AW
    J Biol Chem; 2004 Oct; 279(42):43448-61. PubMed ID: 15297464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
    Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
    Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Ubiquitin Ligases c-Cbl and Cbl-b Negatively Regulate Platelet-derived Growth Factor (PDGF) BB-induced Chemotaxis by Affecting PDGF Receptor β (PDGFRβ) Internalization and Signaling.
    Rorsman C; Tsioumpekou M; Heldin CH; Lennartsson J
    J Biol Chem; 2016 May; 291(22):11608-18. PubMed ID: 27048651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.
    Yang Y; Létard S; Borge L; Chaix A; Hanssens K; Lopez S; Vita M; Finetti P; Birnbaum D; Bertucci F; Gomez S; de Sepulveda P; Dubreuil P
    Blood; 2010 Aug; 116(7):1114-23. PubMed ID: 20484085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
    Lindblad O; Kazi JU; Rönnstrand L; Sun J
    Cell Mol Life Sci; 2015 Nov; 72(22):4399-407. PubMed ID: 26040420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
    Jin B; Ding K; Pan J
    Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
    Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
    Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. I787 provides signals for c-Kit receptor internalization and functionality that control mast cell survival and development.
    Orinska Z; Föger N; Huber M; Marschall J; Mirghomizadeh F; Du X; Scheller M; Rosenstiel P; Goldmann T; Bollinger A; Beutler BA; Bulfone-Paus S
    Blood; 2010 Oct; 116(15):2665-75. PubMed ID: 20595514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.
    An W; Nadeau SA; Mohapatra BC; Feng D; Zutshi N; Storck MD; Arya P; Talmadge JE; Meza JL; Band V; Band H
    Oncotarget; 2015 Apr; 6(12):10498-509. PubMed ID: 25871390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His.
    Pullarkat VA; Pullarkat ST; Calverley DC; Brynes RK
    Am J Hematol; 2000 Dec; 65(4):307-9. PubMed ID: 11074560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.